Surmodics, Inc.
NASDAQ•SRDX
CEO: Mr. Gary R. Maharaj
セクター: Healthcare
業種: Medical - Devices
上場日: 1998-03-04
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
連絡先情報
時価総額
$614.51M
PER (TTM)
-34.8
29.8
配当利回り
--
52週高値
$43.00
52週安値
$25.87
52週レンジ
順位49Top 66.7%
3.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$29.57M-2.55%
直近4四半期の推移
EPS
-$0.37-30.19%
直近4四半期の推移
フリーCF
$904.00K-130.21%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Month Revenue Decline Nine month total revenue $87.6M, reflecting a 6% decrease from prior period levels.
Net Loss Widens Significantly Net loss reached $(14.2M) for nine months, significantly wider than prior year's $(8.1M).
Medical Device Sales Drop Medical Device product sales $27.4M, down 19% driven by SurVeil DCB shipment decrease.
Merger Charges Inflate SG&A SG&A expense increased 14% to $48.0M, primarily due to $10.1M in merger-related charges.
リスク要因
SurVeil DCB Revenue Forecast SurVeil DCB revenue forecast decline of $7.5M in fiscal 2025, offsetting Pounce platform growth.
FTC Merger Litigation Risk Consummation of pending acquisition remains subject to resolution of FTC litigation proceedings.
Recent Cyber Security Incident Experienced June 2025 cyber incident; incurred $1.9M response costs with ongoing reputation risks.
Product Gross Margin Pressure Product gross margin compressed 460 basis points to 50.7% due to SurVeil under-absorption issues.
見通し
2025 Liquidity Sufficiency Existing cash ($32.7M) and credit facility expected to fund 2025 operations and capital expenditures.
Continued Gross Profit Decline Product gross profit and margin expected to decline further due to SurVeil DCB revenue decline.
High Near-Term Expenses SG&A and R&D expenses remain significant, driven by merger charges and Pounce/Sublime platform investment.
Future Financing Potential Long-term cash needs depend on commercialization success; may seek debt or equity financing later.
同業比較
売上高 (TTM)
$1.13B
$854.40M
BVS$563.83M
粗利益率 (最新四半期)
91.5%
XOMA90.6%
87.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
| TCMD | $590.78M | 33.2 | 8.8% | 6.5% |
| VREX | $566.75M | -8.3 | -13.9% | 2.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-3.8%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月28日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年6月30日|提出日: 2025年8月8日|売上高: $29.57M-2.6%|EPS: $-0.37-30.2%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年3月31日|提出日: 2025年4月30日|売上高: $28.09M-12.1%|EPS: $-0.36-2157.1%予想を下回るForm 10-Q - Q1 2025
会計期末: 2024年12月31日|提出日: 2025年1月30日|売上高: $29.92M-2.1%|EPS: $-0.26+366.8%予想を下回るForm 10-K - FY 2024
会計期末: 2024年9月30日|提出日: 2024年11月20日|売上高: $126.08M-4.9%|EPS: $-0.82-645.5%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年6月30日|提出日: 2024年7月31日|売上高: $30.34M-42.2%|EPS: $-0.53-201.9%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年3月31日|提出日: 2024年5月1日|売上高: $31.96M+17.5%|EPS: $0.02-103.2%予想を上回るForm 10-Q - Q1 2024
会計期末: 2023年12月31日|提出日: 2024年2月1日|売上高: $30.55M+22.5%|EPS: $-0.06-90.1%予想を上回るForm 10-K - FY 2023
会計期末: 2023年9月30日|提出日: 2023年11月22日|売上高: $132.58M+32.6%|EPS: $-0.11+94.4%予想を下回る